Patients in the enzalutamide group had longer median time to HRQoL deterioration than did those in the placebo group ( @ months , @ % CI @-@ , vs @ months , @ % CI @-@ ; HR @ , @ % CI @-@ ; p < @ ) in risk of deterioration .